NCT01767948View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Hepatic Impairment
Interventions
DRUG

PCI-32765

PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.

Trial Locations (4)

Unknown

Costa Mesa

Orlando

Knoxville

San Antonio

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01767948 - A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment | Biotech Hunter | Biotech Hunter